Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Extension Study of Del-desiran in Myotonic Dystrophy Type 1
NCT07008469Phase 3Enrolling by invitation
- Sponsor
- Avidity Biosciences
- Start
- Jun 2025
- Primary completion
- Oct 2030
- Countries
- 10
01
Overview
A Phase 3 trial of delpacibart etedesiran in myotonic dystrophy type 1 (DM1), sponsored by Avidity Biosciences. Started Jun 2025; status: enrolling by invitation.
02
Drugs
delpacibart etedesiran
03
Conditions
myotonic dystrophy type 1 (DM1)
Beyond the preview
Go deeper on NCT07008469.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07008469.